Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status

Volume: 111, Issue: 10, Pages: 3739 - 3746
Published: Aug 26, 2020
Abstract
Most clinical trials of non-small-cell lung cancer (NSCLC) exclude patients with poor ECOG performance status (PS). Thus, the efficacy of immune checkpoint inhibitors (ICIs) in patients with poor PS remains unclear. Herein, we used data from a retrospective cohort to assess the potential clinical benefits of ICIs in NSCLC patients with poor PS. Data from NSCLC patients who received ICI monotherapy at 9 institutions between December 2015 and May...
Paper Details
Title
Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status
Published Date
Aug 26, 2020
Volume
111
Issue
10
Pages
3739 - 3746
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.